Who We Are
About Us

Our Mission

Myonexus Therapeutics is a clinical-stage gene therapy company developing first-ever corrective gene therapies for Limb-Girdle muscular dystrophies, debilitating rare diseases with no treatments.

Our Focus

We are developing five novel gene therapies licensed from Nationwide Children’s Hospital, a global leader in neuromuscular disease therapeutic discovery and translational research:

Our Leadership Team

An innovative, strategically focused management team with neuromuscular disease gene therapy, global drug development, and new venture development expertise.

Mike Triplett

Michael Triplett, Ph.D.

President & Chief Executive Officer
Bruce Halpryn

Bruce Halpryn, Ph.D.

Secretary & Chief Operating Officer
Louise Rodino-Klapac

Louise Rodino-Klapac, Ph.D.

Chief Scientific Officer
Peter Kleinhenz

Peter Kleinhenz, MBA

Treasurer & Chief Financial Officer
Brian Price

Brian Price, Ph.D.

Vice President of Pharmaceutical Development

Michael Triplett, Ph.D.
President & CEO, Myonexus Therapeutics, Inc.

Bruce Halpryn, Ph.D.
Secretary & COO, Myonexus Therapeutics, Inc.

Bryan Barber
President and Founder of the LGMD2D Foundation, President and co-founder of ADVANTIS Global Inc.

John Rice, Ph.D.
Chairman, Board of Directors, Myonexus Therapeutics, Inc., Director, Life Sciences CincyTech LLC

Robert Beech
Executive Chairman & Co-founder, Eccrine Systems, Inc.

Our scientific approach is guided by a panel of the community’s pioneers, who offer unparalleled expertise in gene therapy, rare disease and Limb Girdle Muscular Dystrophy.

Reed Clark, Ph.D.
Sr. VP, Pharmaceutical Development, Gene Therapy Ultragenyx Pharmaceutical

Dione Kobayashi, Ph.D.
VP, Preclinical Translation, Cydan

Jerry Mendell, MD
Principal Investigator, Center for Gene Therapy & Director, Neuromuscular Disorders, Nationwide Children’s Hospital

Laura Rufibach, Ph.D.
Co-President, Jain Foundation

Yvan Torrente, Ph.D.
MD, Assistant Professor in Neurology, University of Milan

Matthew Wicklund, MD
Professor and Director, Clinical Neuromuscular Pathology, University of Colorado School of Medicine

Our journey reflects the insights and guidance of patient leaders from LGMD-related organizations.

Bryan Barber (Chair)
Co-Founder, Myonexus Therapeutics and Founder & President, LGMD2D Foundation

Carol Abraham
Director of Community Outreach, Coalition to Cure Calpain3

Scott Frewing
Co-Founder & President, Kurt+Peter Foundation

Lianna Orlando, Ph.D.
Scientific Program Officer, Muscular Dystrophy Association

Josh Thayer, JD
General Counsel, Jain Foundation

Beatrice Vola
President, GFB Onlus

Brad Williams, Ph.D.
Director of Research and Advanced Diagnostics, Jain Foundation